secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2021-10-13T23:59:59+00:00
Accession:  0001104659-21-125849
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics EVP & Chief Commercial Officer William P. Kane resigns effective immediately
--------------------------------------------------------------------------------

- William P. Kane, Jr., EVP and Chief Commercial Officer, resigned on October 8, 2021, effective immediately.
- No reason for the resignation was provided in the filing.
- No successor or interim appointment has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465921125849/0001104659-21-125849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465921125849/tm2129371d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-125849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer